Treatment with Glucagon-Like Peptide-1 Agonist Exendin-4 in a Patient with Hypothalamic Obesity Secondary to Intracranial Tumor
| Autor: | Jill H. Simmons, Christian L. Roth, Ashley H. Shoemaker |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Agonist medicine.medical_specialty Adolescent Intracranial tumor medicine.drug_class Endocrinology Diabetes and Metabolism macromolecular substances Pharmacological treatment Endocrinology Hypothalamic tumors Glucagon-Like Peptide 1 Internal medicine Humans Hypoglycemic Agents Medicine Obesity Brain Neoplasms Venoms business.industry Hypothalamic obesity Neoplasms Germ Cell and Embryonal Severe obesity Glucagon-like peptide-1 Pediatrics Perinatology and Child Health Exenatide Hypothalamic Neoplasms Peptides business medicine.drug |
| Zdroj: | Hormone Research in Paediatrics. 78:54-58 |
| ISSN: | 1663-2826 1663-2818 |
| DOI: | 10.1159/000339469 |
| Popis: | Background/Aims: Patients with hypothalamic tumors frequently experience severe obesity, and its treatment with diet, exercise, and/or pharmacologic treatment has had limited effect. Glucagon-like peptide-1 agonist exenatide (exendin-4), used for treatment of type 2 diabetes, causes persistent weight loss via signaling in the brainstem. Methods: We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor. He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily. Results: Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued. Conclusion: Exenatide resulted in considerable reduction of body weight in a patient with severe hypothalamic obesity. This novel observation requires follow-up clinical studies for establishing the effects of exenatide in patients with disrupted hypothalamic energy regulatory pathways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|